Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 180

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part II, Item 3
Chunk 180
---
 for a period of at least three years following the Effective
Date on terms no less favorable than those applicable to its then-serving officers and directors. The Severance Agreement also reaffirms
Dr. Tesi’s right to indemnification under Nevada law, the Company’s articles of incorporation and bylaws, as amended and in
effect as of the date hereof, and provides for contribution rights in the event indemnification is unavailable.

The Severance Agreement includes
mutual releases of claims, as well as customary provisions relating to confidentiality, non-disparagement, cooperation, and return of
Company property. The Severance Agreement is subject to a seven-day revocation period following execution and shall become effective on
August 12, 2025, if not revoked before (the “Effective Date”).

The foregoing summary of the
Severance Agreement is qualified in its entirety by reference to the full text of the Severance Agreement, which is filed as Exhibit 10.4
hereto and incorporated herein by reference.

Appointment of New Chairman

On August 4, 2025, the Board
appointed J. Kelly Ganjei, an existing member of the Board, as Chairman of the Board, effective as of the Effective Date. Mr. Ganjei has
served on the Board since September 2016 and brings extensive leadership and industry experience to the role of Chairman. Mr. Ganjei will
hold office until the election and qualification of a successor or until either individual’s earlier death, resignation or removal.

Appointment of New President,
Chief Executive Officer and Member of the Board 

On August 4, 2025, the Board
appointed David J. Moss, who was then serving as the Company’s Chief Financial Officer, Treasurer and Secretary, as President, Chief
Executive Officer and as a member of the Board, effective as of the Effective Date. On the same date, the Board also appointed Mr. Moss
as the Company’s Principal Executive Officer, effective immediately. In connection with these appointments, Mr. Moss resigned as
Chief Financial Officer, effective immediately. The Principal Executive Officer position will terminate as of the Effective Date, upon
the effectiveness of Mr. Moss’s appointment as President, Chief Executive Officer and as a member of the Board.

Mr. Moss, age 55, is a co-founder
and has been the Chief Financial Officer since the Company’s formation in September 2015. He also serves as Secretary and Treasurer
and from September 15, 2015 until April 201